IMPROVING HUMAN HEALTH


Targeted Cell Therapies novel delivery technology has the potential to eliminate the need for either viral and lipid vectors, or costly and difficult to manufacture injectables in disease treatment.  Our focus is on the conversion of known injectable therapeutics into easily ingestible drugs that are typically of lower cost with greater patient compliance and reduced adverse side-effects.


Targeted Cell Therapies technology permits the oral delivery of large molecules, avoiding the usual need for injection. The Company’s approach uses yeast derived purified glucan particles (GP) containing nanoplexed nucleic acid (DNA or siRNA) or protein payloads as therapeutic molecules. Following oral administration, the GPs and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or other pathology, the GP payloads are processed by cellular machinery to produce active therapeutics.